myelodysplastic syndromes (MDS) | Page 3 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes

Author(s): 
Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Blood Cancer J
Original Publication Date: 
Sep 2017

No abstract available.

Bone Marrow Diseases: 

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Author(s): 
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Primary Author: 
Platzbecker U
Journal Title: 
Lancet Oncol
Original Publication Date: 
Sep 2017

BACKGROUND:

Bone Marrow Diseases: 

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

Author(s): 
Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N
Primary Author: 
Tefferi A
Journal Title: 
Am J Hematol
Original Publication Date: 
Sep 2017

A 27-gene panel was used for next-generation sequencing (NGS) in 179 patients (median age 73 years) with primary

Bone Marrow Diseases: 

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

Author(s): 
Cogle CR, Reddy SR, Chang E, Papoyan E, Broder MS, McGuire M, Binder G
Primary Author: 
Cogle CR
Journal Title: 
Leuk Res
Original Publication Date: 
Aug 2017

Bone Marrow Diseases: 

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

Author(s): 
Patel SS, Gerds AT
Primary Author: 
Patel SS
Journal Title: 
Curr Hematol Malig Rep
Original Publication Date: 
Aug 2017

Quality of life (QOL) and symptom burden are important measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide spectrum of physical and psychosocial effects. Thus, the development and application of PROs can provide meaningful information to facilitate communication and assist in follow up care. Disease-specific measures can more accurately reflect the full breadth of functional restrictions and symptoms.

Bone Marrow Diseases: 

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Event Date: 
Sat, 09/16/2017 -
8:00am to 3:30pm
Conference Event Type: